市場調查報告書

世界藥用玻璃管市場增長,趨勢,預測(2020-2025)

Global Pharmaceutical Glass Tubing Market - Growth, Trends, and Forecast (2020 - 2025)

出版商 Mordor Intelligence LLP 商品編碼 946369
出版日期 內容資訊 英文 120 Pages
商品交期: 2-3個工作天內
價格
世界藥用玻璃管市場增長,趨勢,預測(2020-2025) Global Pharmaceutical Glass Tubing Market - Growth, Trends, and Forecast (2020 - 2025)
出版日期: 2020年06月01日內容資訊: 英文 120 Pages
簡介

2019年,藥用玻璃管市場規模達到123.5億美元,預計到2025年將達到207.5億美元。我們還預計在2020年至2025年的預測期內,複合年增長率將達到5.5%。用於製藥的玻璃管的製造中使用的製造工具和製造技術非常複雜。這種複雜性主要是由玻璃管的多種用途引起的。大多數製藥應用都需要符合一組規格的玻璃管。如今,製造方法正迅速發展以滿足這些廣泛的規格類別。根據歐洲藥物和藥物成癮監測中心的最新數據,2019年報告在瑞典分發了517,381支注射器。

  • 世界上增長最快的製藥行業正在推動市場增長。引入嚴格的立法以確保國產藥物的質量和完整性,已增加了玻璃在藥品包裝產品中的使用。此外,在預測期內,製藥行業對無菌醫療包裝產品的需求增加將進一步推動市場增長。 由於玻璃介質中封裝的藥物數量增加,對玻璃基注射劑,安瓿瓶等的需求正在增加。根據世界衛生組織(WHO)的數據,全世界約有4.22億人患有糖尿病。數量的增加增加了對青黴素的需求,從而促進了市場的增長。
  • 玻璃管和注射器是美國最常用的包裝形式。根據Pharmaceutical-technology.com網站的資料,在美國排名前十的藥物中,有七種是使用玻璃包裝的。 Opdivo,Avastin,Herceptin和Kettleda以20至50 cc大小的玻璃瓶出售。
  • 美國在藥品市場的消費和發展方面也具有壟斷地位。根據STAT的數據,到2023年,美國的處方藥支出預計將從2019年的5,000億美元增至6,000億美元,並有望進一步推動美國藥用玻璃管市場。
  • 諸如肖特(SCHOTT)這樣的供應商在世界範圍內佔有很大的份額,肖特是一家專門從事玻璃和玻璃陶瓷領域的全球領先公司。該公司擁有超過14萬噸的生產能力,並在歐洲,南美和亞洲設有多個生產基地,是玻璃管的領先製造商之一。
  • COVID-19的大流行給藥用玻璃管行業帶來了嚴峻的形勢。全國範圍的封鎖使玻璃管行業的情況更加惡化。

本報告對藥用玻璃管市場進行了調查,並分析了市場概況,市場增長因素和障礙因素的分析,市場規模趨勢和按應用/地區劃分的預測,競爭情況,主要公司的概況,我們提供全面的信息,例如市場機會。

內容

第1章簡介

第2章調查方法

第3章執行摘要

第4章市場動態

  • 市場概況
  • 市場增長因素
    • 新興國家製藥業的發展
    • 可回收性提高了玻璃的商業價值
  • 市場約束因素
    • 改善替代來源
  • 產業價值鏈分析
  • 五力分析
    • 新進入的威脅
    • 買方/消費者的議價能力
    • 供應商議價能力
    • 替代產品的威脅
    • 加劇競爭

第5章市場細分

  • 通過申請
    • 瓶 小瓶
    • 安瓿
    • 墨盒
    • 注射器
  • 按地區
    • 北美
    • 歐洲
    • 亞太地區
    • 拉丁美洲
    • 中東和非洲

第6章競爭情況

  • 主要供應商資料
    • Schott AG
    • Nipro Pharma Corporation
    • Corning Incorporated
    • Nippon Electric Glass Co. Ltd.
    • Accu-Glass LLC.
    • Richland Glass Co. Inc.
    • Cangzhou Four-star Glass Co. Ltd.
    • LINUO Group
    • DWK Life Sciences GmbH
    • Aimer Products Limited

第7章 投資分析

第8章 市場的未來展望

目錄
Product Code: 69991

The pharmaceutical glass tubing market was valued at USD 12.35 billion in 2019 and is projected to reach USD 20.75 billion by 2025, registering a CAGR of 5.5% over the forecast period, 2020 - 2025. The manufacturing tools and fabrication techniques that are being used to manufacture pharmaceutical tubing have become extraordinarily complex. The complexity is primarily being driven by multiple applications in which the tubing is used. The most pharmaceutical application requires tubing that meets a set of specifications, and currently, the manufacturing methods are rapidly evolving to accommodate these broad categories of specifications. According to the European Monitoring Centre for Drugs and Drug Addiction, the 2019 report, 517,381 syringes are distributed in Sweden.

  • The rapidly growing pharmaceutical industry across the world is boosting the growth of the market. The introduction of stringent laws to enhance the quality and integrity of domestically manufactured drugs is leading to an increase in the use of glass for pharmaceutical packaging products. Additionally, the increasing demand for sterile medical packaging products from the pharmaceutical industries would further drive the growth of the market over the forecast period.
  • The increasing number of drugs that are being packaged in the glass medium is driving the demand for glass-based injectables, ampules, etc. According to the World Health Organization (WHO), around 422 million people have diabetes around the world. The increase in this number is increasing the demand for penicillin, which is, thereby, contributing to the growth of the market.
  • The glass bottles and syringes are the most used form of packaging in the United States. According to the website "Pharmaceutical-technology.com," seven of the top ten drugs sold in the united states are packaged using glass. The Opdivo, Avastin, Herceptin, and Keytruda are sold in glass bottles, which are of 20 to 50 cc sizes, while the most sold drug Humira in sold in Syringes.​
  • The United States also dominates the pharmaceutical market, both in consumption and development. According to STAT, prescription drug spending in the nation is considered to add up to USD 600 billion by 2023, up from an estimated USD 500 billion in 2019, which is further expected to drive the market for the pharmaceutical glass tubing market in the region.​
  • Vendors in the market, such as Schott, which is a prominent technology group specializing in the area of glass and glass-ceramics across the globe, have a significant market share. With the production capacity of more than 140,000 tons and multiple production sites in Europe, South America, and Asia, the company is one of the leading manufacturers of glass tubes, rods, and profiles. The company manufactures more than 60 different glass types in a large variety of dimensional and cosmetic specifications that are based on a standardized production process.
  • Moreover, the COVID -19 pandemic has put forth a demanding situation for the players in the pharmaceutical glass tubing industry. The widespread of the pandemic and the humanitarian toll is taken by it is primarily making it challenging for the players in the market to respond. The nationwide lockdowns have further worsened this situation for the glass tubing industry.
  • Several vendors in the market are aiding the fight against the pandemic through critical supplies. For instance, Corning is supplying its products from glass tubing for diagnostic test kits to vials for clinical drug trials for vaccines, to providing corning valor glass packaging in order to help fill the gap for the projected drug shortages. The company is also providing assistance with glass packaging, or any need for consumables from its Life Sciences portfolio for vaccine process development.

Key Market Trends

Application of Bottles is Witnessing Significant Growth

  • Glass bottles are amongst the primary packaging material that has been widely used in the pharmaceutical industry. A considerable number of pharmaceutical formulations have been packaged using glass bottles, and they are usually the first choice of packaging materials. ​
  • According to FEVE, the European Container Glass Federation, container glass production among FEVE members grew 217 thousand tonnes from 2018 levels and reached at 21,755 thousand tonnes and 78,662 million units, respectively in currently.
  • The rapidly growing pharmaceutical industry across the various region of the world is boosting the growth of the market. The demand for pharmaceutical glass is majorly arising from stable economies, such as the United States and Canada. The increasing pharmaceutical production in these countries is further increasing the demand. According to IQVIA, pharmaceutical sales in the United States in 2019 was USD 491 billion. and global pharmaceutical sales were USD 1033 billion.
  • Moreover, the increasing demand for injectable pharmaceuticals is significantly driving the growth of glass bottles in the pharmaceutical sector. The robust market for oncology and other high-potency drugs (such as antibody conjugates, steroids, and IV fluids that require quick onset of action) is expected to be the segment's key growth driver.
  • Moreover, due to the superior recycling property of the glass, it has gained full acceptance in the pharmaceutical glass tubing market. According to the Institute of Scrap Recycling Industris, Inc., the recycled glass is the substitute of 70% of the raw material used in making new glass. The initiatives of glass recycling are adding value to glass as a commodity.
  • Over 130 million tonnes of glass is currently being produced annually, out of which 46% are of container glass. According to Recovery Magazine, recycling for container glass is the highest, which is estimated to be 32% globally. Effective recycling is driving the pharmaceutical industry to adopt glass packaging solutions apart from its other benefits.

Asia-Pacific to Witness the Fastest Growth

  • The demand for pharmaceutical glass tubing is majorly arising from prominent pharma nations in the Asia-Pacific region, such as India and China. The increasing pharmaceutical production in these countries is further increasing the demand.
  • Further, manufacturers and suppliers are focusing on shifting their base to China and India, as a result of increasing opportunities offered by the pharmaceutical industry in these countries, especially in the generics sector.
  • Also, China's National Health Commission forecasts that the total size of the Chinese healthcare industry is anticipated to reach CNY 16 trillion (USD 2.39 trillion) by 2030. According to the Chinese Center for Disease Control and Prevention, Institute for Health Metrics and Evaluation, China has reached a health "tipping point," with chronic conditions replacing infectious diseases as the leading causes of early deaths in the nation of 1.4 billion people.​ Huge investments anticipated to control this scenario are expected to drive the demand from China.
  • Moreover, India is the source of 60,000 generic medicine brands across 60 therapeutic categories and manufactures more than 500 different Active Pharmaceutical Ingredients (APIs). The Department of Pharmaceuticals is aiming to make the country a hub for end-to-end drug discovery under its 'Pharma Vision 2020.
  • The companies are significantly expanding their manufacturing and production activities in the region. For instance, in Aug 2019, Germany-based Schott carried out a capacity expansion at its greenfield pharmaceutical glass tubing plant in Jinyun, Zhejiang, China. The new plant will enable the company to participate in the advancement of the Chinese pharmaceutical packaging industry. The company will invest EUR 60 million in the first phase to install a yearly capacity of up to 20,000 tons. The production is scheduled to initiated by the end of 2020.
  • Similarly, in December 2019, German pharmaceutical and healthcare products packaging supplier Gerresheimer opened a second production site in India. The new plant will increase the production capacity to meet the growing demand from the country's pharma sector. The plant will also support the company's vial production from tubular glass for pharmaceutical and diagnostic applications, as well as ampoules.

Competitive Landscape

The pharmaceutical glass tubing market is highly consolidated, owing to the presence of many dominant and large players in the market. The market is consolidated with the key players adopting strategies, such as product innovation, to stay ahead of the competition. Some of the players in the market are Schott AG, Nipro Pharma Corporation, Corning Incorporated, Richland Glass Co. Inc., among others.

  • April 2020 - Corning Inc. supported China's effort to help mitigate the impact of COVID-19 on the regional pharmaceutical supply chain by donating its Type I borosilicate glass tubing. This high-quality tubing will be converted into 5 million to 10 million ampoules and vials that will then be supplied to the Chinese pharmaceutical companies for parenteral packaging of drug therapies.
  • November 2019 - Schott AG has announced its plan to double its manufacturing capacity in India, by infusing a total of EUR 47 million (including its existing investment of EUR 21 million). The company is also planning to inject additional investments of EUR 26 million for another tank facility in 2020.

Reasons to Purchase this report:

  • The market estimate (ME) sheet in Excel format
  • 3 months of analyst support

Table of Contents

1 INTRODUCTION

  • 1.1 Study Deliverables
  • 1.2 Study Assumptions
  • 1.3 Scope of the Study

2 RESEARCH METHODOLOGY

3 EXECUTIVE SUMMARY

4 MARKET DYNAMICS

  • 4.1 Market Overview
  • 4.2 Market Drivers
    • 4.2.1 Growth of Pharmaceutical Industry in Emerging Economies
    • 4.2.2 Commodity Value of Glass Increased with Recyclability
  • 4.3 Market Restraints
    • 4.3.1 Increased Relevance of Alternate Sources
  • 4.4 Industry Value Chain Analysis
  • 4.5 Porters 5 Force Analysis
    • 4.5.1 Threat of New Entrants
    • 4.5.2 Bargaining Power of Buyers/Consumers
    • 4.5.3 Bargaining Power of Suppliers
    • 4.5.4 Threat of Substitute Products
    • 4.5.5 Intensity of Competitive Rivalry

5 MARKET SEGMENTATION

  • 5.1 Application
    • 5.1.1 Bottles
    • 5.1.2 Vials
    • 5.1.3 Ampoules
    • 5.1.4 Cartridges
    • 5.1.5 Syringes
  • 5.2 Geography
    • 5.2.1 North America
      • 5.2.1.1 United States
      • 5.2.1.2 Canada
    • 5.2.2 Europe
      • 5.2.2.1 Germany
      • 5.2.2.2 United Kingdom
      • 5.2.2.3 France
      • 5.2.2.4 Rest of Europe
    • 5.2.3 Asia Pacific
      • 5.2.3.1 China
      • 5.2.3.2 India
      • 5.2.3.3 Japan
      • 5.2.3.4 Rest of Asia-Pacific
    • 5.2.4 Latin America
    • 5.2.5 Middle East and Africa

6 COMPETITIVE LANDSCAPE

  • 6.1 Key Vendor Profiles
    • 6.1.1 Schott AG
    • 6.1.2 Nipro Pharma Corporation
    • 6.1.3 Corning Incorporated
    • 6.1.4 Nippon Electric Glass Co. Ltd.
    • 6.1.5 Accu-Glass LLC.
    • 6.1.6 Richland Glass Co. Inc.
    • 6.1.7 Cangzhou Four-star Glass Co. Ltd.
    • 6.1.8 LINUO Group
    • 6.1.9 DWK Life Sciences GmbH
    • 6.1.10 Aimer Products Limited

7 INVESTMENT ANALYSIS

8 FUTURE OF THE MARKET